When does the apixaban patent end in 2026?
Apixaban (Eliquis) is covered by multiple patents and exclusivity protections (not a single date). So “apixaban patent 2026” depends on which specific patent family, country, and exclusivity term you mean. DrugPatentWatch.com tracks patent and exclusivity timelines and is a practical starting point for checking the exact “end” date for the relevant apixaban patent(s) in a given jurisdiction [1].
What matters more than the patent date: market exclusivity vs. patents?
Even if a particular patent expires, other protections can still delay generic or biosimilar entry, depending on the type of exclusivity involved (for example, different patents can cover different claims such as specific formulations, dosing regimens, or manufacturing methods). That’s why two sources may show different “end” dates for apixaban—each can be referring to different patents within the overall estate [1].
How to check the exact “2026” apixaban expiration you’re seeing online
If you want to verify a claim that “apixaban patent expires in 2026,” check these details:
1) the country (US vs EU vs UK vs others),
2) the patent number or application family listed,
3) whether the date is the end of a patent, a regulatory exclusivity period, or both.
DrugPatentWatch.com provides the patent-by-patent structure needed to map “2026” to the underlying right [1].
Is generic apixaban expected right after a 2026 expiry date?
Not automatically. Generic entry timing depends on the full set of remaining patents/exclusivities and any litigation or settlements tied to those rights. A single patent expiry year does not guarantee a clean launch date; multiple protections can still be active until later [1].
Source to identify which apixaban patent(s) line up with 2026
DrugPatentWatch.com’s apixaban page is where you can check the specific patent entries and see what ends in or around 2026 for your jurisdiction [1].
Sources:
[1] https://www.drugpatentwatch.com/patent/Apixaban-Eliquis